How to store MK-677
This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
Also called: Ibutamoren, Ibutamoren mesylate, Ibutamoren mesilate, MK-0677, MK0677, LUM-201, L-163,191.
Growth hormone secretagogues (ghrelin receptor) · Non-peptide ghrelin-receptor agonist and growth hormone secretagogue.
Comes as: Trial oral tablets, Trial oral capsules, Trial flavored oral solution.
Mixed with: No approved home diluent or injectable formulation. An older trial used a prepared 2 mg/mL flavored oral solution..
- OraGrowtH210 tablets came in 9, 18 and 36 mg strengths; they were not to be divided, chewed or crushed.
- Oral liquids, tablets and research powders are not sterile injectable medicines.
- No human injection regimen or peptide-style vial reconstitution schedule was established.
Before mixing: OraGrowtH210 trial tablets: 15-25°C (59-77°F). This does not establish storage or shelf life for unrelated online products.
After mixing: No validated shelf life or home-mixing storage schedule was found for consumer oral liquids.
Related to MK-677 (ibutamoren)
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- GHRP-2: A peptide that releases growth hormone and can increase hunger.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Unapproved ibutamoren capsules (MK-677) found to contain undisclosed anabolic steroid, Therapeutic Goods Administration · 2026
- 503A Categories Update for September 2024, FDA · FDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting, FDA · 2024
- Anaphylaxis, NHS · NHS · 2023
- Scheduling delegate's final decisions, April 2018, Therapeutic Goods Administration · 2018
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
- EU/3/17/1882 - orphan designation for treatment of growth hormone deficiency, European Medicines Agency
- Information on Select Dietary Supplement Ingredients and Other Substances, FDA
- Search Orphan Drug Designations and Approvals, FDA · FDA
- Supply unlicensed medicinal products (specials), MHRA · MHRA
- Unauthorized workout supplements may pose serious health risks, Health Canada
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.